Literature DB >> 17042033

Gene duplications in 21-hydroxylase deficiency: the importance of accurate molecular diagnosis in carrier detection and prenatal diagnosis.

B Ezquieta1, M Beneyto, R Muñoz-Pacheco, R Barrio, M Oyarzabal, J L Lechuga, C Luzuriaga, F Hermoso, S Quinteiro, S Martinez.   

Abstract

BACKGROUND: The detection of 21-OH deficiency (21OHD) carriers in the general population requires that misinterpretations of apparently severe mutations in alleles carrying duplicated genes be avoided. Prenatal treatment prevents virilization in female fetuses and genetic counseling may be offered to couples in which one partner is either a patient or a carrier. This paper proposes a semiquantitative PCR method involving primer extension that distinguishes the severe point mutation Q318X in single gene copy alleles from the normal/nondeficient variant in gene-duplicated alleles. SAMPLES AND METHODS: DNA from 65 individuals carrying Q318X variants, that of 85 partners of 21OHD carriers or patients, and one fetal sample (as well as the DNA of his family) were analyzed. 21OHD alleles were studied by gene-specific PCR/allele-specific oligonucleotides hybridization for common mutations, Southern analysis, complementary direct sequencing and microsatellite typing. Primer extension analysis of the Q318X variants using fluorescent dideoxynucleotides was performed on CYP21A2 gene-specific PCR-amplified DNA samples from controls, patients, potential carriers and prenatal samples.
RESULTS: Different fluorescence patterns were seen for the severe mutation (single gene copy) and the nondeficient (gene-duplicated) alleles carrying Q318X. The normal/mutant fluorescence peak (N/M) ratio was < 1 in all heterozygous carriers (mean 0.83; min. 0.70; max. 0.95). In all normal individuals carrying the gene-duplicated Q318X normal variant, the N/M ratio was > 1 (mean 1.69; min. 1.44; max. 2.02).
CONCLUSION: The proposed method discriminated between the severe Q318X mutation and the normal Q318X variant in gene duplication, and could be a useful complementary tool in prenatal diagnosis and carrier detection. 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17042033     DOI: 10.1002/pd.1584

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  7 in total

1.  A sequence variation in 3'UTR of CYP21A2 gene correlates with a mild form of congenital adrenal hyperplasia.

Authors:  S Menabò; A Balsamo; L Baldazzi; M Barbaro; A Nicoletti; V Conti; P Pirazzoli; A Wedell; A Cicognani
Journal:  J Endocrinol Invest       Date:  2011-04-26       Impact factor: 4.256

Review 2.  Congenital Adrenal Hyperplasia (CAH) due to 21-Hydroxylase Deficiency: A Comprehensive Focus on 233 Pathogenic Variants of CYP21A2 Gene.

Authors:  Paola Concolino; Alessandra Costella
Journal:  Mol Diagn Ther       Date:  2018-06       Impact factor: 4.074

3.  Molecular Diagnosis of Congenital Adrenal Hyperplasia in Iran: Focusing on CYP21A2 Gene.

Authors:  Bahareh Rabbani; Nejat Mahdieh; Mohammad-Taghi Haghi Ashtiani; Mohammad-Taghi Akbari; Ali Rabbani
Journal:  Iran J Pediatr       Date:  2011-06       Impact factor: 0.364

Review 4.  Molecular Diagnosis of Steroid 21-Hydroxylase Deficiency: A Practical Approach.

Authors:  María Arriba; Begoña Ezquieta
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-29       Impact factor: 5.555

5.  Molecular diagnosis of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Tania Mayvel Espinosa Reyes; Teresa Collazo Mesa; Paulina Arasely Lantigua Cruz; Adriana Agramonte Machado; Emma Domínguez Alonso; Henrik Falhammar
Journal:  BMC Endocr Disord       Date:  2020-11-09       Impact factor: 2.763

Review 6.  Genes and Pseudogenes: Complexity of the RCCX Locus and Disease.

Authors:  Cinzia Carrozza; Laura Foca; Elisa De Paolis; Paola Concolino
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-30       Impact factor: 5.555

7.  Assessing clinical utility of preconception expanded carrier screening regarding residual risk for neurodevelopmental disorders.

Authors:  Paranchai Boonsawat; Anselm H C Horn; Katharina Steindl; Alessandra Baumer; Pascal Joset; Dennis Kraemer; Angela Bahr; Ivan Ivanovski; Elena M Cabello; Michael Papik; Markus Zweier; Beatrice Oneda; Pietro Sirleto; Tilo Burkhardt; Heinrich Sticht; Anita Rauch
Journal:  NPJ Genom Med       Date:  2022-07-29       Impact factor: 6.083

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.